News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (308 of 354). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 354). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (35 of 354). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 266 of 354 items have one.
Medicare spending rises after private equity buys hospices
A study of for-profit hospices acquired by private equity firms found that Medicare spending rose by 5.9% per hospice stay after acquisition, compared with similar for-profit hospices that weren't acquired. …
Read at Medical Xpress →Starting Alzheimer's treatment earlier increases benefits to patients and society
New treatments that can slow the progression of Alzheimer's disease could provide significant lifetime benefits to patients and society, with even greater benefits when initiated earlier, according to new research from the USC Schaeffer Center for Health Policy & Economics.
Read at Medical Xpress → Archived copy (7 Oct 2026), Internet ArchiveExperts provide policy roadmap to reduce dementia risk
A national panel of experts has issued the strongest call yet for the Department of Health and Social Care to overhaul how it approaches dementia prevention…
Why it matters: A national panel of experts has issued a call for the Department of Health and Social Care to overhaul its approach to dementia prevention.
Read at Medical Xpress →Safe, low-cost Alzheimer's drug demonstrates efficacy against sickle cell anemia
Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle cell anemia in the future. …
Why it matters: Memantine, a long-approved and cost-effective Alzheimer's drug, shows potential to benefit patients with sickle cell anemia in the future.
Read at Medical Xpress →Follow new items in a feed reader: Atom feed.